ID Biomedical Corporation Appoints Dr. Robert N. Bryan as Vice President, Development

Strategic Insights -

ID Biomedical Corporation has announced the appointment of Dr. Robert N. Bryan as Vice President, Development, a move that is expected to bring significant expertise in DNA-based testing to the company. Dr. Bryan has a proven track record of developing and introducing FDA-approved DNA-based tests, and his experience will be invaluable to ID Biomedical as it moves its DNA tests through product development. With a portfolio of research programs focused on infectious diseases, cancer, and genetic disease, ID Biomedical is poised to make significant strides in the field of biotechnology.

Key Takeaways:

  • Dr. Robert N. Bryan has been appointed as Vice President, Development at ID Biomedical Corporation, bringing 15 years of product development experience in DNA-based testing.
  • Dr. Bryan has held management positions at Affymetrix, Gen-Probe, Genta, and Molecular Biosystems, and was responsible for introducing the first FDA-approved DNA-based test while at Gen-Probe.
  • ID Biomedical is developing a nucleic acid diagnostic system and related products based on its proprietary SLT and CPT technologies.
  • The company's research programs include tests for seven infectious diseases, a cancer, and a genetic disease through its own research and collaborations.
  • ID Biomedical's subsidiary, ID Vaccine Corp., is developing a subunit vaccine against tuberculosis.

Statistics:

  • ID Biomedical has 15 years of experience in product development, including 15 years of management experience in DNA-based testing for Dr. Bryan.
  • The company has a portfolio of research programs focused on seven infectious diseases, a cancer, and a genetic disease.
  • ID Biomedical has developed 19 DNA-based culture confirmation tests, with Dr. Bryan leading the project team that introduced the first FDA-approved DNA-based test.
  • The company is developing a nucleic acid diagnostic system and related products using its SLT and CPT technologies.

Sources:

  • ID Biomedical Corporation press release, September 14, 1995
  • Business Wire, September 14, 1995